Product Description
For overweight/obesity (otherwise healthy) patients
Mechanisms of Action: NPY2 Agonist
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Obesity|Overweight
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06352424 |
U1111-1293-4672 | P1 |
Completed |
Obesity|Overweight |
2025-02-24 |
12% |
2025-03-13 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT05751226 |
NCT05751226 | P1 |
Completed |
Obesity|Overweight |
2024-08-01 |
2% |
2024-09-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|